Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer

Journal of Urology

Volumn 167, Issue 5, 2002, Pages 2017-2024

  Okihara, Koji ^b   Cheli, Carol D ^b   Partin, Alan W ^b   Fritche, Herbert A ^b   Chan, Daniel W ^b   Sokoll, Lori J ^b   Brawer, Michael K ^b   Schwartz, Morton K ^b   Vessella, Robert L ^b   Loughlin, Kevin R ^b   Johnston, Dennis A ^b   Babaian, R Joseph ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; COMPARATIVE STUDY; DEVICE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 0036229722     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)65075-6     Document Type: Article

References (18)

1. A complex between prostate-specific antigen and α-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: Assay of the complex improves clinical sensitivity for cancer
2. Prostate-specific antigen in serum occurs predominantly in complex with α-1-antichymotrypsin
3. Double-label time-resolved immunofluormetric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin
4. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
5. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA
6. Can complexed PSA be used as a single test for detecting prostate cancer?
7. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
8. Measurement of complexed PSA improves specificity for early detection of prostate cancer
9. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
10. Comtemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: Impact of changing disease demographics
11. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer
12. Ratio of free or complexed prostae-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
13. Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia
14. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
15. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer
16. Can complexed prostate-specific antigen and prostatic volume enhance the prostate cancer detection in men with total PSA values between 2.5 and 4.0 ng/ml?
17. A method of comparing the area under receiver operating chacteristic curves derived from the same cases